Patents by Inventor Charles Roland Wolf
Charles Roland Wolf has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 9255256Abstract: A bacterial cell containing a functional cytochrome P450 monooxygenase system, said cell comprising a genetic construct capable of expressing a cytochrome P450 and a genetic construct capable of expressing, separately from said cytochrome P450, a cytochrome P450 reductase wherein the N-terminus of the cytochrome P450 and the N-terminus of the cytochrome P450 reductase are each adapted to allow functional coupling of said cytochrome P450 and said cytochrome P450 reductase within said cell. A bacterial cell containing a cytochrome P450 comprising a genetic construct encoding, and capable of expressing, said cytochrome P450 wherein the cytochrome P450 comprises an N-terminal portion which directs the cytochrome P450 to a cellular compartment of membrane of the bacterial cell. The bacterial cells are useful as, for example, bioreactors, in drug testing and mutagenicity testing and as a source of cytochrome P450.Type: GrantFiled: February 18, 2003Date of Patent: February 9, 2016Inventors: Charles Roland Wolf, Thomas Herbert Friedberg, Michael Patrick Pritchard
-
Patent number: 8809619Abstract: The invention relates to the generation of mouse models of drug metabolism in which clusters of genes that are involved in drug metabolism have been knocked out. The development of new drugs and chemicals for therapeutic use or for other purposes is extremely complex. Of particular importance is the understanding of how these chemical agents are handled in the body, whether they have appropriate pharmacokinetics and whether, as a consequence of metabolism, any safety issues arise. Many of the proteins that are involved in the metabolism, disposition and elimination of drugs are members of multigene families that exhibit very marked species differences in gene number, function and regulation. For these reasons, experiments carried out in laboratory animals to establish routes of metabolism or toxicity can be severely compromised and, as a consequence, do not faithfully represent the human situation.Type: GrantFiled: October 17, 2008Date of Patent: August 19, 2014Assignee: ITI Scotland LimitedInventors: Nico Scheer, Charles Roland Wolf
-
Patent number: 8624079Abstract: The present invention relates to transgenic non-human animals, tissues or cells derived therefrom and methods of producing them. The transgenic non-human animals or tissues or cells derived therefrom provide a system capable of expressing human proteins responsible for drug metabolism in place of the homologous endogenous non-human animal proteins and for the controlled expression of human genes introduced into the animal so that the expression of the human genes is regulated in a manner more closely analogous to that seen in vivo in humans. One aspect of the invention relates to the use of a human DNA sequence comprising at least part of introns 6 and/or 7 of the human PXR gene.Type: GrantFiled: June 4, 2008Date of Patent: January 7, 2014Assignee: ITI Scotland LimitedInventors: Charles Roland Wolf, Nico Scheer
-
Publication number: 20130029928Abstract: There is provided compositions comprising perfluorooctanoic acid (PFOA) or a salt, derivative or variant thereof. There is also provided uses, methods therapeutic systems and combination therapies relating to PFOA.Type: ApplicationFiled: February 18, 2011Publication date: January 31, 2013Inventors: Clifford Roy Elcombe, Charles Roland Wolf, Anna Louise Westwood
-
Patent number: 8212105Abstract: The present invention relates to transgenic non-human animals, tissues or cells derived therefrom and methods of producing them. The transgenic non-human animals or tissues or cells derived therefrom provide a system capable of expressing human proteins responsible for drug metabolism in place of the homologous endogenous non-human animal proteins and for the controlled expression of human genes introduced into the animal so that the expression of the human genes is regulated in a manner more closely analogous to that seen in vivo in humans.Type: GrantFiled: May 26, 2010Date of Patent: July 3, 2012Assignee: ITI Life SciencesInventors: Charles Roland Wolf, Nico Scheer, Nicole Faust
-
Publication number: 20110119780Abstract: The invention relates to a method for screening for the effects of non-genotoxic carcinogens in an animal model. The invention also relates to animal models that are suitable for use in such a method, and cell lines derived from these animals for in vitro screening purposes. More specifically, the invention relates to a transgenic rodent animal which has been humanised for the nuclear transcription factors CAR, PXR and PPAR?, and in which the endogenous equivalent genes have been rendered inoperable.Type: ApplicationFiled: March 9, 2009Publication date: May 19, 2011Applicant: ITI SCOTLAND LIMITEDInventors: Charles Roland Wolf, Clifford Roy Elcombe
-
Publication number: 20100333222Abstract: The invention relates to the generation of mouse models of drug metabolism in which clusters of genes that are involved in drug metabolism have been knocked out. The development of new drugs and chemicals for therapeutic use or for other purposes is extremely complex. Of particular importance is the understanding of how these chemical agents are handled in the body, whether they have appropriate pharmacokinetics and whether, as a consequence of metabolism, any safety issues arise. Many of the proteins that are involved in the metabolism, disposition and elimination of drugs are members of multigene families that exhibit very marked species differences in gene number, function and regulation. For these reasons, experiments carried out in laboratory animals to establish routes of metabolism or toxicity can be severely compromised and, as a consequence, do not faithfully represent the human situation.Type: ApplicationFiled: October 17, 2008Publication date: December 30, 2010Inventors: Nico Scheer, Charles Roland Wolf
-
Publication number: 20100257620Abstract: The present invention relates to transgenic non-human animals, tissues or cells derived therefrom and methods of producing them. The transgenic non-human animals or tissues or cells derived therefrom provide a system capable of expressing human proteins responsible for drug metabolism in place of the homologous endogenous non-human animal proteins and for the controlled expression of human genes introduced into the animal so that the expression of the human genes is regulated in a manner more closely analogous to that seen in vivo in humans. One aspect of the invention relates to the use of a human DNA sequence comprising at least part of introns 6 and/or 7 of the human PXR gene.Type: ApplicationFiled: June 4, 2008Publication date: October 7, 2010Applicant: ITI Scotland LimitedInventors: Charles Roland Wolf, Nico Scheer
-
Publication number: 20100240751Abstract: A perfluoroctanoic acid or a salt or an ester thereof; perfluorosuberic acid, perfluoroheptanoic acid, perfluorohexanoic acid, perfluoropentanoic acid, perfluorobutanoic acid or perfluoropropionic acid or a salt or an ester any thereof; or perfluoroctane are useful in treating diabetes, obesity, hypercholesterolaemia, hyperlipidaemia, cancer, inflammation or other conditions in which modulation of lipid or eicosanoid status or function may be desirable.Type: ApplicationFiled: January 19, 2010Publication date: September 23, 2010Inventors: Clifford Roy Elcombe, Charles Roland Wolf
-
Publication number: 20100235928Abstract: The present invention relates to transgenic non-human animals, tissues or cells derived therefrom and methods of producing them. The transgenic non-human animals or tissues or cells derived therefrom provide a system capable of expressing human proteins responsible for drug metabolism in place of the homologous endogenous non-human animal proteins and for the controlled expression of human genes introduced into the animal so that the expression of the human genes is regulated in a manner more closely analogous to that seen in vivo in humans.Type: ApplicationFiled: May 26, 2010Publication date: September 16, 2010Applicant: ITI LIFE SCIENCESInventors: Charles Roland Wolf, Nico Scheer, Nicole Faust
-
Patent number: 7759541Abstract: The present invention relates to transgenic non-human animals, tissues or cells derived therefrom and methods of producing them. The transgenic non-human animals or tissues or cells derived therefrom provide a system capable of expressing human proteins responsible for drug metabolism in place of the homologous endogenous non-human animal proteins and for the controlled expression of human genes introduced into the animal so that the expression of the human genes is regulated in a manner more closely analogous to that seen in vivo in humans.Type: GrantFiled: June 4, 2007Date of Patent: July 20, 2010Assignee: ITI Life SciencesInventors: Charles Roland Wolf, Nico Scheer, Nicole Faust
-
Publication number: 20100138935Abstract: We provide reporter gene constructs incorporating nucleic acid sequences from a promoter region of a gene or set of genes whose expression is modified in response to external or internal changes in the cellular environment such as biochemical stress or toxic conditions. The promoters are operatively linked to nucleic acid sequences chosen on the basis of the ease with which their transcription and/or translation products may be assayed so that the reporter gene constructs can provide a system capable of detecting intracellular conditions. Also described are transfected cell lines including the constructs and transgenic non-human animal models including the constructs.Type: ApplicationFiled: July 15, 2005Publication date: June 3, 2010Inventors: Anthony John Clark, Helen Elizabeth Clark, Charles Roland Wolf, Christopher Bruce Alexander Whitelaw, Clifford Roy Elcombe, Kenneth Brown
-
Patent number: 7700822Abstract: The present invention relates to non-human transgenic animals, tissues and/or cells derived therefrom having depleted or ablated cytochrome P450 reductase (CPR) expression, methods of producing such animals, tissues and/or cells, and methods of using such animals, tissues and/or cells. Non-human transgenic animals, tissues and or cells derived therefrom of the present invention may be used for, but non exclusively, in both in vivo and in vitro screening of therapeutic agents, drug development, drug metabolism/disposition studies and studying disease states, pregnancy, fetal development, modulation of hormone function and hormone levels, and other pathways and/or substrate metabolism in which cytochrome P450 plays a role.Type: GrantFiled: November 27, 2002Date of Patent: April 20, 2010Assignee: Cancer Research Technology LimitedInventors: Charles Roland Wolf, Colin J. Henderson
-
Publication number: 20100093017Abstract: The present invention provides cell lines that have been transfected with adenovirus expression vectors so that they express at least one metabolically competent or functional cytochrome P450 enzyme. The invention also includes methods of their use, especially in toxicology screens.Type: ApplicationFiled: October 7, 2009Publication date: April 15, 2010Inventors: Charles Roland Wolf, Shaohong Ding
-
Publication number: 20090010888Abstract: The invention provides a method of enhancing the effectiveness of pesticides, as well as pesticidal formulations. Furthermore, it also provides the means for the de novo rational design of pesticides. The present invention also relates to a method of screening agents for potential use in insecticides, particularly against mosquitoes.Type: ApplicationFiled: June 22, 2007Publication date: January 8, 2009Applicants: University Court of the University of Dundee, The University of LiverpoolInventors: Mark John Ingraham Paine, Charles Roland Wolf, Lesley Ann McLauchlin
-
Publication number: 20090013417Abstract: A method of introducing at least one human cytochrome P450 into a non-human animal c ell in which corresponding endogenous P450 enzyme activities have been disabled, thus the method provides a way of using a non-human animal cell to make predictions regarding P450-mediated metabolism in a human. The present invention also provides transgenic non-human animals produced by the method of the invention and uses therefor, especially in assessing xenobiotic/drug metabolism and toxicity.Type: ApplicationFiled: February 3, 2005Publication date: January 8, 2009Applicant: IMPERIAL CANCER RESEARCH TECHNOLOGY LIMITEDInventors: Charles Roland Wolf, Colin J. Henderson
-
Publication number: 20080148416Abstract: The present invention relates to transgenic non-human animals, tissues or cells derived therefrom and methods of producing them. The transgenic non-human animals or tissues or cells derived therefrom provide a system capable of expressing human proteins responsible for drug metabolism in place of the homologous endogenous non-human animal proteins and for the controlled expression of human genes introduced into the animal so that the expression of the human genes is regulated in a manner more closely analogous to that seen in vivo in humans.Type: ApplicationFiled: June 4, 2007Publication date: June 19, 2008Inventors: Charles Roland Wolf, Nico Scheer, Nicole Faust
-
Publication number: 20030215915Abstract: A bacterial cell containing a functional cytochrome P450 monooxygenase system, said cell comprising a genetic construct capable of expressing a cytochrome P450 and a genetic construct capable of expressing, separately from said cytochrome P450, a cytochrome P450 reductase wherein the N-terminus of the cytochrome P450 and the N-terminus of the cytochrome P450 reductase are each adapted to allow functional coupling of said cytochrome P450 and said cytochrome P450 reductase within said cell. A bacterial cell containing a cytochrome P450 comprising a genetic construct encoding, and capable of expressing, said cytochrome P450 wherein the cytochrome P450 comprises an N-terminal portion which directs the cytochrome P450 to a cellular compartment of membrane of the bacterial cell. The bacterial cells are useful as, for example, bioreactors, in drug testing and mutagenicity testing and as a source of cytochrome P450.Type: ApplicationFiled: February 18, 2003Publication date: November 20, 2003Inventors: Charles Roland Wolf, Thomas Herbert Friedberg, Michael Patrick Pritchard
-
Patent number: 6566108Abstract: A bacterial cell containing a functional cytochrome P450 monooxygenase system, said cell comprising a genetic construct capable of expressing a cytochrome P450 and genetic construct capable of expressing, separately from said cytochrome P450, a cytochrome P450 reductase, wherein each of the cytochrome P450 and the cytochrome P450 reductase have at their N-terminus a bacterial signal peptide. The cytochrome P450 and the cytochrome P450 reductase may be encoded by different constructs or the same construct. A bacterial cell containing a cytochrome P450 comprising a genetic construct encoding, and capable of expressing, said cytochrome P450 wherein the cytochrome P450 has, at is N-terminal, a bacterial signal peptide. The bacterial cells are useful as, for example, bioreactors, in drug testing and mutagenicity testing and as a source of cytochrome P450.Type: GrantFiled: May 17, 1999Date of Patent: May 20, 2003Assignee: University of DundeeInventors: Charles Roland Wolf, Thomas Herbert Friedberg, Michael Patrick Pritchard
-
Publication number: 20030028906Abstract: The present invention relates to a recombinant genetic material which can be operably linked to protein encoding sequence comprising an expression control sequence having at least one promoter region and at least one repressor region such that basal expression in a tissue where the protein is required to be expressed is reduced whilst allowing induction of expression of the protein encoding sequence. Suitably the promoter is a p450 type promoter whilst suitably it is the p450 CYP1A1 promoter of the rat. The invention further provides a method of manufacturing proteins for polypeptides in the method of manufacturing or recombinant construct for transgene induction.Type: ApplicationFiled: June 27, 2002Publication date: February 6, 2003Inventors: Anthony John Clark, Charles Roland Wolf